Diabetic Retinopathy News and Research RSS Feed - Diabetic Retinopathy News and Research

In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
IU researchers create virtual tissue model of diabetic retinopathy

IU researchers create virtual tissue model of diabetic retinopathy

By combining data on optometry patient's eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. [More]
Thousands of volunteers join clinical trial to help transform early detection of diabetic eye disease

Thousands of volunteers join clinical trial to help transform early detection of diabetic eye disease

More than 4,500 people from Liverpool with diabetes have volunteered to join a clinical trial funded by the National Institute for Health Research to help transform early detection of diabetic eye disease. [More]
Pain reliever appears to help preserve vision in animal model of retinal degeneration

Pain reliever appears to help preserve vision in animal model of retinal degeneration

A pain medicine that potently activates a receptor vital to a healthy retina appears to help preserve vision in a model of severe retinal degeneration, scientists report. [More]
Darapladib drug can protect against vision loss in diabetic patients

Darapladib drug can protect against vision loss in diabetic patients

Researchers at Queen's University Belfast and University College London have discovered that a drug, originally developed to treat cardiovascular disease, has the potential to reduce diabetes related blindness. [More]
Scientists developing cost-effective retinal scanner for early diagnosis of glaucoma, diabetic retinopathy

Scientists developing cost-effective retinal scanner for early diagnosis of glaucoma, diabetic retinopathy

A European group of scientists are working on the development of a breakthrough, compact, cost-effective retinal scanner that will play a key role in targeting the early diagnosis of retinal diseases that are worldwide leading causes of blindness. [More]
ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy. [More]
Potential new intraocular treatment based on RAS manipulation can prevent or reverse diabetic retinopathy

Potential new intraocular treatment based on RAS manipulation can prevent or reverse diabetic retinopathy

Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model. [More]
Diabetic patients at risk for developing retinal diabetic neuropathy

Diabetic patients at risk for developing retinal diabetic neuropathy

A University of Iowa-led study of diabetes-related vision impairment holds good news -- and some bad news -- for patients with signs of these disorders. [More]
International researchers make crucial discovery on formation, growth of blood vessels

International researchers make crucial discovery on formation, growth of blood vessels

As blood vessels grow, the cells that compose them must make a choice between forming side-branches or expanding the vessel surface and increasing its diameter. Now Prof. Holger Gerhardt at the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association and his international research teams have made a crucial disovery about this process: the cells can behave as a collective, moving in the same direction together. [More]
New study explores mechanisms that control size, shape of tubular organ systems

New study explores mechanisms that control size, shape of tubular organ systems

A new study from the group of Holger Gerhardt in collaboration with Katie Bentley's Lab addresses a long standing question in the wider field of developmental biology and tissue patterning in general, and in the vascular biology field in particular: 'What are the fundamental mechanisms controlling size and shape of tubular organ systems'. [More]
Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

At the Israeli Society for Vision and Eye Research conference on March 10, the MedInsight Research Institute and Center for Drug Repurposing at Ariel University presented the latest findings on positive user-reported outcomes of the repurposed drug dipyridamole in treating pterygium and related dry-eye symptoms. [More]
Anticancer drug restores hearing in neurofibromatosis patients

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing. [More]
UWF scanning technology increases identification of diabetic retinopathy

UWF scanning technology increases identification of diabetic retinopathy

In a national clinical trial led by Joslin Diabetes Center's Beetham Eye Institute, ultrawide field scanning technology significantly improved the ability of experts at a remote central location to identify diabetic retinopathy in a patient, and to judge whether the eye disease warranted referring the patient to an ophthalmologist for further care. [More]
Study reveals another clue to workings of trachoma

Study reveals another clue to workings of trachoma

Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form. [More]
Researchers identify genetic mutations that lower complications associated with diabetes

Researchers identify genetic mutations that lower complications associated with diabetes

The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries. [More]
First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR). [More]
New study reveals better treatment options for proliferative diabetic retinopathy

New study reveals better treatment options for proliferative diabetic retinopathy

This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes. [More]
Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment. [More]
Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD). [More]

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA. [More]
Advertisement